Roche, the world’s largest biotech company and a global leader in diagnostics, was founded in 1896 by Fritz Hoffmann-La Roche in Basel, Switzerland. Today, Roche CEO Thomas Schinecker leads the company’s CHF 61.5 billion business and a global workforce of over 103,000 employees across more than 100 countries. Appointed Group CEO in March 2023, Schinecker brought two decades of experience within Roche itself, having risen from management trainee in 2003 to CEO of Roche Diagnostics before taking the helm of the entire group. Under his leadership, Roche has delivered strong financial results, including 7% sales growth in 2025 and a 13% increase in core operating profit.
(Suggested: Novartis CEO Email & Net Worth – Vas Narasimhan Salary)
Thomas Schinecker – Quick Facts
Roche Competitors
Roche operates in the highly competitive global pharmaceuticals and diagnostics industry. The key competitors of Roche include:
- Novartis – Swiss pharma rival; global leader in innovative medicines
- Johnson & Johnson – Diversified healthcare; pharmaceuticals and medical devices
- Pfizer – Major US pharma company; vaccines, oncology, immunology
- AstraZeneca – UK-Swedish pharma; oncology and rare diseases
- AbbVie – US biopharma; immunology and oncology leader
- Merck & Co. – US pharma; Keytruda oncology franchise
- Sanofi – French pharma; immunology, rare diseases, vaccines
- Eli Lilly – US pharma; diabetes, obesity, Alzheimer’s
Thomas Schinecker Net Worth 2026 – Roche CEO Salary
As of 2026, Thomas Schinecker’s net worth is estimated at approximately $15–20 million USD, based on his cumulative Roche compensation, share holdings (valued at approximately $1.6 million in direct stock ownership), and personal assets. His pay is modest relative to US pharma peers, reflecting Swiss corporate governance norms and Roche’s founding-family ownership structure.
Roche CEO Compensation Breakdown (FY2025)
Roche Net Worth 2026 – Is Roche Profitable?
Yes, Roche is a highly profitable company and one of the largest healthcare businesses in the world. Under CEO Thomas Schinecker, Roche delivered strong results in 2025 with sales growth of 7% at constant exchange rates.
Roche Financial Summary (FY2025)
(Recommended: Pfizer CEO Email & Net Worth – Albert Bourla Salary)
Roche CEO Email Address | Thomas Schinecker Contact
Below are the official contact details and social media profiles for Roche CEO Thomas Schinecker:
Career & Education – Company, University, & College
Thomas Schinecker’s career is unique among major pharma CEOs — he is a pure scientist-turned-executive who spent his entire corporate career at a single company. Below is his complete career timeline:
Thomas Schinecker Career Timeline
Thomas Schinecker joined Roche in 2003 as a management trainee in the Diagnostics division immediately after completing his Ph.D. at NYU. Over the next 16 years, he held multiple international leadership roles across the Diagnostics business, gaining deep operational experience in markets across Asia, Europe, and the Americas.
In 2019, Schinecker was appointed CEO of Roche Diagnostics, where he led the division through one of its most consequential periods. During the COVID-19 pandemic, he spearheaded Roche’s rapid development and global deployment of COVID-19 test kits, making Roche the world’s largest provider of SARS-CoV-2 diagnostic tests. His leadership during the pandemic cemented his reputation as a decisive, science-driven executive.
In March 2023, Schinecker succeeded long-serving CEO Severin Schwan, who transitioned to the role of Chairman of the Board of Directors. Schinecker’s appointment marked a generational shift at Roche and the continuation of a tradition of promoting from within.
(Related: Johnson & Johnson CEO Email & Net Worth – Joaquin Duato)
Education
Thomas Schinecker Wiki – Age, Family, & More
Roche CEO Thomas Schinecker (age 50) was born on April 23, 1975, in Simbach am Inn, Bavaria, Germany, to an Austrian father and a German mother. From the age of nine, he grew up in Singapore as the son of an ABB employee, attending the German school there. This multicultural upbringing across three continents gave Schinecker a uniquely global perspective from childhood.
Schinecker is married and has three children. The family has lived near Rotkreuz, Switzerland, since 2017. He keeps his family life private, and details about his wife’s identity are not publicly disclosed.
Schinecker is one of the few Fortune 500 CEOs who holds a Ph.D. in Molecular Biology and actually worked in a laboratory as a scientist before moving into management. He is known for his passion for science and innovation, stating on his LinkedIn that he is “passionate about science, and committed to positively impacting people’s lives through healthcare.”
Leadership & Achievements
- IFPMA President (2025) – Elected President of the International Federation of Pharmaceutical Manufacturers and Associations
- BCR Chair (2025) – Appointed Chair of the Biopharmaceutical CEOs Roundtable
- COVID-19 Testing Leader – Led Roche Diagnostics’ rapid development of COVID-19 test kits during the pandemic
- Pipeline Expansion – Overseeing development of up to 19 new medicines to be launched by end of the decade
- 12 Positive Late-Stage Readouts – Achieved in 2025, reinforcing Roche’s industry-leading R&D pipeline
- Obesity Market Entry – Leading Roche’s strategic push into the GLP-1/obesity therapeutics market
- World Health Summit Speaker – Regular speaker at major global healthcare conferences
About Roche
F. Hoffmann-La Roche AG, commonly known as Roche, is a Swiss multinational healthcare company headquartered in Basel, Switzerland. Founded in 1896, Roche is the world’s largest biotech company and a global leader in in-vitro diagnostics. The company operates through two main divisions:
Roche trades on the SIX Swiss Exchange under the ticker symbol ROG (non-voting shares: RO). The Hoffmann and Oeri families hold approximately 50.1% of voting shares, providing long-term stability. Through its US subsidiary Genentech (acquired in 2009) and Japanese subsidiary Chugai Pharmaceutical, Roche operates one of the most productive R&D pipelines in the pharmaceutical industry, with over 100 ongoing clinical studies.
Frequently Asked Questions (FAQ)
Who is the current CEO of Roche?
The current CEO of Roche is Dr. Thomas Schinecker, who was appointed Group Chief Executive Officer in March 2023. He succeeded Severin Schwan, who moved to the role of Chairman of the Board. Schinecker previously served as CEO of Roche Diagnostics and holds a Ph.D. in Molecular Biology from NYU.
What is Thomas Schinecker’s net worth in 2026?
As of 2026, Thomas Schinecker’s net worth is estimated at approximately $15–20 million USD, based on his cumulative compensation at Roche and disclosed share holdings. His direct stock ownership in Roche is valued at approximately $1.6 million.
What is the Roche CEO’s salary?
Thomas Schinecker’s total compensation for 2025 was CHF 10.2 million (~$13.3 million USD), comprising a ~CHF 3.5 million base salary, ~CHF 3.0 million in annual bonus shares, ~CHF 3.3 million in long-term incentives, and ~CHF 0.4 million in pension and benefits. His compensation is modest relative to US pharma CEO peers.
What is the Roche CEO’s email address?
Roche CEO Thomas Schinecker’s email address is [email protected]. He can also be reached via LinkedIn. For general inquiries, contact Roche’s headquarters in Basel, Switzerland at +41 61 688 1111.
What did Thomas Schinecker do before becoming Roche CEO?
Before becoming Group CEO, Thomas Schinecker served as CEO of Roche Diagnostics from 2019 to 2023. He joined Roche in 2003 as a management trainee after earning his Ph.D. from NYU, and spent 20 years within the company in various international leadership roles across the Diagnostics division. He is notable for leading Roche’s COVID-19 test kit development during the pandemic.
Is Roche a profitable company?
Yes, Roche is highly profitable. In 2025, the company reported group sales of CHF 61.5 billion (+7% at constant exchange rates), core operating profit of CHF 21.8 billion (+13%), and IFRS net income of CHF 13.8 billion. Roche has a market capitalization of approximately CHF 295 billion (~$380 billion).
Article last updated:March 2026March 4, 2026
Disclaimer: All information presented in this article has been compiled from publicly available sources, including Roche’s official annual reports, corporate press releases, and reputable news outlets. This content is provided for informational purposes only and does not constitute financial or investment advice.